Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03595917 · ClinicalTrials.gov registry record · Phase 1
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
A Phase 1 study of B-cell Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, sponsored by Marlise Luskin, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT03595917 is a Phase 1 study of B-cell Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis that is actively recruiting participants, run by Marlise Luskin, MD. The registered enrollment target is 40 participants, below the 87-participant average among 21 other B-cell Acute Lymphoblastic Leukemia trials with a reported enrollment target (54% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT03595917, a Phase 1 study of B-cell Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, is actively recruiting participants, sponsored by Marlise Luskin, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myeloid Leukemia (CML) in lymphoid blast crisis. BCR-ABL+ B-ALL is also called Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL). It is expected that 40-65 people will take part in this research study. * ABL001 * Dasatinib (Sprycel®) * Prednisone * Blinatumomab
Conditions Studied
Interventions
- DRUG Prednisone
- DRUG Dasatinib
- DRUG Blinatumomab
- DRUG ABL001
Study Locations (4)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-07-24 |
| Est. Completion | 2027-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03595917
The ClinicalTrials.gov registry entry for NCT03595917 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 87-participant average among 21 other B-cell Acute Lymphoblastic Leukemia trials with a reported enrollment target (54% lower). The listed sponsor is Marlise Luskin, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with B-cell Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 4 interventions - of which Prednisone is the first listed.
NCT03595917 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT03595917 about?
NCT03595917 is a clinical study titled "ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML". This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myeloid Leukemia (CML) in lymphoid blast crisis. BCR-A...
What is the current status of trial NCT03595917?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2018-07-24. Estimated completion is 2027-11-01.
What conditions does trial NCT03595917 study?
This clinical trial studies the following conditions: B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL.
What interventions are being tested in trial NCT03595917?
The interventions under investigation include: Prednisone (DRUG), Dasatinib (DRUG), Blinatumomab (DRUG), ABL001 (DRUG).
Who is sponsoring clinical trial NCT03595917?
This trial is sponsored by Marlise Luskin, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03595917 being conducted?
This trial has 4 study locations across Illinois, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
RECRUITING · Phase 1
-
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
RECRUITING · Phase 1
-
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
RECRUITING · Phase 1
-
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RECRUITING · Phase 1
Explore more on PlainTrial
B-cell Acute Lymphoblastic Leukemia
All registered trials for this condition
Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis
All registered trials for this condition
Illinois
All trials with a study site in Illinois
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.